A VR View: Severe Uncontrolled Asthma: Phenotypes, Endotypes, and Treatment Response Decisions

REGISTER NOW!
Already Registered?
SIGN IN

WEBCAST DATE

Friday, November 08, 2019

09:15 PM Eastern    08:15 PM Central    07:15 PM Mountain    06:15 PM Pacific

PROGRAM FEATURES

• VIRTUAL REALITY SETS provided to all attendees for viewing this presentation only
• Interactive, case-based learning environment
• Create your own personalized poster
• iPads provided to enhance learning experience and enable real-time Q&A

FACULTY

Michael E. Wechsler, MD, MMSc
Director, The Cohen Family Asthma Institute
Professor
Department of Medicine
Division of Pulmonary, Critical Care and Sleep Medicine
National Jewish Health
Denver, CO

LEARNING OBJECTIVES

After completing the educational activity, learners should be better able to:

• Review how the varying inflammatory profiles of the different asthma phenotypes can inform the development of new treatments for severe uncontrolled asthma
• Evaluate the usefulness of phenotypic- or endotypic-specific biomarkers in diagnosing, classifying, and controlling severe uncontrolled asthma
• Develop treatment plans individualized for each patient with severe asthma accounting for specific patient factors, current evidence-based guidance, and the clinical profiles of current treatments

AGENDA

I. Introduction

II. Pathogenesis Primer for Asthma
  A. Review of molecular involvement in asthma inflammation and type 2 immune processes
    • Severe phenotypes – atopic and non-atopic
       – Variable clinical, molecular, and immunologic features
       – IgE, FeNO, eosinophilia, and comorbidities
  B. VR Animation: a view of immune cells, inflammatory cytokines, and the process resulting in the underlying pathology of asthma with nasal mucosal cross-talk

III. Diagnosis of Asthma
  A. Guidelines establishing diagnosis and associated comorbidities
  B. Diagnostic testing methods
  C. Differentiating between other chronic respiratory conditions
  D. Asthma phenotypes/subtypes and implications for treatment

IV. Asthma Treatment for Moderate to Severe Disease
  A. Goals of treatment: achieving disease control, preventing exacerbations, reducing morbidity and mortality
  B. Pharmacologic treatment options and monitoring response
    • Biological targeted monoclonal antibodies – clinical trials data (omalizumab, mepolizumab, reslizumab, and benralizumab)
    • Type 2 biomarkers – utility and interpretation
    • Decreased exacerbations and daily corticosteroid dose, improved lung function (FEV1)
  C. Recent data on targeted therapies
    • Dupilumab – efficacy and safety data in moderate to severe asthma
    • VR Animation: current inflammatory targets for severe asthma and mechanisms of action of monoclonal antibodies for IgE, IL-4, IL-5, and IL-13

V. Conclusions

VI. Questions and Answers

TARGET AUDIENCE

This initiative is designed to meet the educational needs of pulmonologists, allergists, immunologists, ENTs and primary care physicians who are involved in the healthcare of patients with moderate-to-severe asthma.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com.

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Med Learning Group prior to the live event at info@medlearninggroup.com

Copyright © 2019 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.